MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of
GHENT, Belgium -- (BUSINESS WIRE) --
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D.
“We are excited to have Grégoire join our executive team at this pivotal moment for MRM Health, on the cusp of late-stage clinical development for our lead candidate MH002 in ulcerative colitis and pouchitis, from our proprietary CORAL platform designed to harness the full power of the gut microbiome to develop effective and safe therapeutics,” said Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health. “Grégoire’s extensive expertise in corporate development, combined with his strategic acumen, will be crucial as we continue to advance our pipeline and expand our reach.”
Mr. Franoux will lead the company’s business development and corporate strategy, focusing on forging strategic partnerships and driving growth. He brings 20 years of experience in strategic planning, licensing, business development and corporate finance within the biotechnology sector. He joins MRM Health from Belfius Bank, where he was spearheading Corporate Finance and Capital Markets activities in the Life Sciences sector. Prior to joining Belfius, Gregoire held senior business development positions at Oxurion, Gruenenthal GmbH and Flamel Technologies. He holds an M.S. in Biotechnology from ESIEE Paris, an M.S. in International Finance from IAE Aix-Marseille, and an Executive M.B.A. from INSEAD.
“It is an exciting time to join the MRM Health team as the company makes important progress advancing next-generation LBPs for inflammatory, CNS and metabolic diseases. I look forward to optimizing the value of MRM’s potentially life-altering therapies and delivering them to patients in need,” commented Grégoire Franoux.
In addition, MRM Health welcomes Ron Robison, M.D., to its Board of Directors. Ron, who previously served as Vice President at AbbVie, brings over three decades of experience in drug development and commercialization. Ron also served in global senior pharmaceutical R&D leadership roles at several organizations, including Mallinckrodt Medical, Sanofi/Sterling Winthrop, Nycomed, Amersham Health, Abbott and Head of R&D and Chief Medical Officer at Solvay Pharmaceuticals. Ron has overseen the approval of more than 20 new molecular entities worldwide with over ten innovative clinical indications obtained under FDA breakthrough therapy designation. Dr. Robison holds an M.D. from the Oregon Health Sciences University, an M.S. in Medical Informatics/Biomedical Engineering from the University of Utah, and a B.S. from Oregon State University.
MRM Health Chairman Werner Cautreels added, “We are thrilled to have Ron join our Board. His deep industry knowledge and experience progressing assets through clinical and global regulatory development will be invaluable as we continue to grow and develop potentially transformative therapies.”
-Ends-
About MRM Health
MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical development in Ulcerative Colitis and/or in the orphan disease indication Pouchitis. MRM Health leverages its proprietary disruptive CORAL® technology platform to design microbiome-based biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. A significant differentiator is the ability to manufacture these consortia as single drug substance in a single standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.
- 旺旺23财年营收、利润双增长,看好下一个增量爆款O泡
- 《盛夏缤纷》开机,白旭含三组写真大片曝光 氛围感超绝
- 天花板级油画作品!艺术家陈岚《自在莲莲》系列画作,8月20日开拍,中国现代画莲第一人”陈岚绘画作品
- 麦澜德PI-ONE系统亮相CMEF 助力打造智慧型盆底中心
- 开启聪明烟机时代 美菱引领行业新风尚
- 《江河之上》收视率强势破二 陈数再塑经典女性角色
- 仲景宛西制药创新文化传播形式,立足地道药材,助推产业发展
- DMS 健美大赛新疆站在乌鲁木齐圆满落幕,多民族选手共展风采
- Adrian Ridge Appointed CEO of Nikkiso Clean Energy & Industrial Gases Group
- 关爱患病儿童,让“花朵”向阳而生
- Sustainable Apparel Coalition更名为Cascale
- 智慧酒店新选择:皓丽智显屏助力酒店行业数字化升级
- 2024西施音乐节红蓝大战热血开启 4月26日开票
- Valeura Energy Inc.: Precautionary Suspension of Wassana Production
- 春日Coffee Walk 邂逅都市中的繁花浪漫 品味拉瓦萨的春意盎然
- 智慧合作,畅享未来:华为与AI富呗商城共创智能电商新纪元
- 中华健康养生之道:探寻传统智慧,塑造健康生活
- 苏格兰传感技术初创企业Novosound正蓄势待发,计划开拓亚太市场
- Meltwater launches new global Partner Program to fuel customer success
- 刺猬英语为何受家长青睐?读完这篇文章你就知道了!
- 阿拉善SEE助力电影《雪豹》,倡导人与自然和谐共处
- 《她们的好时光》第一季收官:张碧晨姜妍周扬青惊喜闺蜜局治愈满满
- 【望京之星】解读望京|北京朝阳崛起的“新贵”区域
- Guidewire Jasper版本提高了财产与意外伤害保险公司商业险的灵活性,并增强了整个产品组合的功能
- At the Yacht Club de Monaco it is time for the Monaco Energy Boat Challenge
- 酱香型白酒的酿造工艺
- FPT Software Partners with Siemens to Provide Low-code Platform Mendix in Korean and Japanese Market
- 8月迎来暑气热潮 解暑美食对抗炎热
- 长江电力公布2023年年度业绩 营收利润双增长
- 5亿㎡产业集群、影响4亿消费人群 北方建陶展销盛会即将启幕
推荐
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯